Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), in compliance with
Nasdaq Marketplace Rule 4350(b)(1)(B), which requires separate
disclosure of receipt of an audit opinion that contains a going concern
qualification, disclosed that our Annual Report (Form 10-K) for the year
ended December 31, 2007 contains a going concern qualification from our
independent registered public accounting firm, KPMG LLP.
This announcement does not represent any change or amendment to our 2007
financial statements or to our Annual Report, filed on Form 10-K with
the SEC, on March 17, 2008.
About Nastech
Nastech is a clinical-stage biopharmaceutical company focusing on the
development and commercialization of innovative therapeutic products
based on its proprietary molecular biology-based nasal drug delivery
technology and its proprietary ribonucleic acid interference technology.
Nastech and its collaboration partners are developing products for
multiple therapeutic areas including diabetes, obesity, osteoporosis,
autism, respiratory diseases and inflammatory conditions. Additional
information about Nastech is available at http://www.nastech.com.
Nastech Forward Looking Statements
Statements made in this press release may be forward-looking statements
within the meaning of Federal Securities laws that are subject to
certain risks and uncertainties and involve factors that may cause
actual results to differ materially from those projected or suggested.
Factors that could cause actual results to differ materially from those
in forward-looking statements include, but are not limited to: (i) the
ability of Nastech or a subsidiary to obtain additional funding; (ii)
the ability of Nastech or a subsidiary to attract and/or maintain
manufacturing, research, development and commercialization partners;
(iii) the ability of Nastech, a subsidiary and/or a partner to
successfully complete product research and development, including
preclinical and clinical studies and commercialization; (iv) the ability
of Nastech, a subsidiary and/or a partner to obtain required
governmental approvals; and (v) the ability of Nastech, a subsidiary
and/or a partner to develop and commercialize products that can compete
favorably with those of competitors. Additional factors that could cause
actual results to differ materially from those projected or suggested in
any forward-looking statements are contained in Nastech's most recent
periodic reports on Form 10-K and Form 10-Q that are filed with the
Securities and Exchange Commission. Nastech assumes no obligation to
update and supplement forward-looking statements because of subsequent
events.
Bookmarken
